Top Ten most popular articles on Pharmafile.com this week!
pharmafile | June 14, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma
Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! The story prompted calls for greater transparency and more open science as researchers were outraged that such important findings could be suppressed.
Meanwhile MPs in the House of Commons discussed using Crown Use licensing rules to break Vertex’s IP rights over Orkambi. The discussion marked a new stage in the longstanding stale mate between the US firm and the British government.
In other enws an expert witness aat the trial of J&J said the US healthcare conglomerate was in some ways worse than Purdue Pharma while Novartis Pharma got a new CEO. Check out this weeks top 10!
Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime.
Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.
French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with Paul Hudson, CEO at Novartis Pharmaceuticals.
AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on its SGLT2 inhibitor Farxiga (dapagliflozin), demonstrating that the drug successfully reduced the progression of kidney disease or renal death in patients with type-2 diabetes (T2D).
The role Johnson & Johnson played in the opioid crisis was ‘in some ways worse’ than that of Purdue Pharma, an expert witness said in the Oklahoma trial of J&J.
Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which indicate that Soliqua (insulin glargine and lixisenatide) met its primary endpoint in the treatment of type 2 diabetes patients.
New type 2 diabetes data for Novo’s oral semaglutide show that the glucagon-like peptide-1 (GLP-1) analogue achieved “statistically significant blood sugar reductions and statistically significant reduction of body weight” compared to rivals Jardiance and Victoza.
AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the sum of £330 million that the firm budgeted for in 2013.
MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and giving UK patients access to the £104,000 a year drug.
Pfizer supressed data suggesting that their drug Enbrel reduced the risk of patients developing Alzheimer’s disease by 64%.
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has …